Drug Characteristics
  • Formulation

    Injection: 50mg

    Caution when prescribing and administering amphotericin: ensure the dose administered matches the specific formulation.

  • Dose

    Cryptococcal meningitis : 1 mg/kg IV increasing to 4 mg/kg IV once a day. A test dose should be administered prior to the first infusion (not necessary if transferring from an alternative amphotericin preparation).

    Histoplasma capsulatum :

    Moderate–severe disseminated

    1 mg/kg IV increasing to 3 mg/kg once a day for 14 days followed by maintenance with itraconazole 200 mg oral suspension three times a day then 200 mg orally twice a day for at least 12 months.

    CNS disease :

    Dose up 5 mg/kg/day for 4–6 weeks.

    Visceral leishmaniasis :

    A total dose of 21–30 mg/kg of body weight given over 10–21 days. This differs from the regime described in the main text and specialist advice is recommended. Other fungal infections (e.g. ‘azole’ resistant candida): 1 mg/kg IV increasing to 3 mg/kg once a day, according to the infection severity. Doses should be titrated upwards from 1 mg/kg/day

    Other fungal infections (e.g. ‘azole’ resistant candida): 1 mg/kg IV increasing to 3 mg/kg once a day, according to the infection severity.

    Doses should be titrated upwards from 1 mg/kg/day

  • Side Effects

    Reduced renal toxicity compared to conventional amphotericin B. Reduced incidence of infusion-related side effects compared to conventional amphotericin.

  • Interactions

    AmBisome ® therapy has been administered for as long as 3 months, with a cumulative amphotericin dose of 16.8 g without significant toxicity

  • Renal

    Dose as in normal renal function

  • Hepatic

    No dosage adjustment currently recommended

  • Pregnancy

    Compatible

  • Other Information